Story perspectives

BrainsWay's FDA Clearance Boosts Shares and Treatment Speed

9/18/2025

26 3

Summary

Story summary

BrainsWay Ltd. received FDA clearance for an accelerated treatment protocol using its Deep TMS system for major depressive disorder (MDD).
The protocol enables five sessions per day over six days, reducing treatment time significantly.
Clinical trials indicated similar outcomes to standard treatment in depression score reductions and remission rates.
Following the announcement, BrainsWay's shares increased by 11.9%.
The global neuromodulation devices market is expected to grow, boosting BrainsWay's growth potential.

1 of 1

Story summary

BrainsWay Ltd. received FDA clearance for an accelerated treatment protocol using its Deep TMS system for major depressive disorder (MDD).
The protocol enables five sessions per day over six days, reducing treatment time significantly.
Clinical trials indicated similar outcomes to standard treatment in depression score reductions and remission rates.
Following the announcement, BrainsWay's shares increased by 11.9%.
The global neuromodulation devices market is expected to grow, boosting BrainsWay's growth potential.